NanoViricides, Inc. (NYSE‑American: NNVC) filed an application for Orphan Drug Designation with the U.S. Food and Drug Administration on February 12 2026 for its lead candidate NV‑387, a host‑mimetic nanomedicine intended to treat mpox.
The Orphan Drug Designation provides a range of incentives, including tax credits for qualified clinical trials, exemption from certain FDA user fees, and up to seven years of market exclusivity after approval. These benefits are designed to accelerate regulatory review and reduce the cost of bringing a treatment for a rare disease to market, positioning NV‑387 for potential stockpiling contracts and rapid deployment in outbreak settings.
NV‑387 works by mimicking human cell surface receptors to trap and neutralize orthopoxviruses. Preclinical studies have shown strong antiviral activity in lethal mouse orthopoxvirus models, and a Phase I safety trial completed in 2025 reported no adverse events. The platform’s broad‑spectrum potential extends beyond mpox to RSV, COVID‑19, influenza, smallpox, and measles, underscoring its versatility as a nanomedicine technology.
NanoViricides is a development‑stage company with no reported revenue and no debt, supported by a comfortable interest‑coverage ratio. The company operates its own cGMP‑capable manufacturing facility, which can reduce development time and costs. In addition to the mpox filing, NanoViricides submitted an ODD for measles on February 10 2026 and has received approval to begin a Phase II trial of NV‑387 for mpox in the Democratic Republic of Congo.
"NV‑387, as an effective drug would be an important tool to fight MPox in the USA and worldwide, when approved after clinical trials," said Dr. Anil R. Diwan, PhD. He added, "MPXV clade IIb is endemic in the USA. Further, the more contagious MPXV Clade Ia/Ib continues to simmer in Africa and is mutating, posing a potential global pandemic threat." Dr. Diwan also noted, "Treating a patient and providing the drug prophylactically to contacts would eliminate the need for quarantine and loss of valuable school time. An Orphan Drug Designation would help us tremendously in the mission of regulatory development and approval of NV‑387 to treat Measles."
"No significant market reaction was reported for this filing. Historically, similar ODD filings have produced mixed responses; for example, the measles ODD filing on February 10 saw a positive reaction, while a prior Master Services Agreement announcement in December 2025 was met with a negative reaction."
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.